27348973 | Overexpression of RRM2 in gastric cancer cell promotes their invasiveness via AKT/NF-??B signaling pathway. | Pharmazie | 2016 May | Zhong Z | - |
22569992 | An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: implications for adjuvant treatment. | Cancer | 2013 Jan 15 | Fisher SB | doi: 10.1002/cncr.27619 |
23466567 | Small interfering RNA (siRNA)-mediated silencing of the M2 subunit of ribonucleotide reductase: a novel therapeutic strategy in ovarian cancer. | Int J Gynecol Cancer | 2013 May | Zhang M | doi: 10.1097/IGC.0b013e318287e2b3. |
22884145 | Overexpression of catalytic subunit M2 in patients with ovarian cancer. | Chin Med J (Engl) | 2012 Jun | Wang LM | - |
19250552 | Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis. | Mol Cancer | 2009 Feb 28 | Zhang K | doi: 10.1186/1476-4598-8-11. |
27801665 | CREB1 directly activates the transcription of ribonucleotide reductase small subunit M2 and promotes the aggressiveness of human colorectal cancer. | Oncotarget | 2016 Nov 22 | Fang Z | doi: 10.18632/oncotarget.12938. |
27845331 | BRCA1-regulated RRM2 expression protects glioblastoma cells from endogenous replication stress and promotes tumorigenicity. | Nat Commun | 2016 Nov 15 | Rasmussen RD | doi: 10.1038/ncomms13398. |
18941749 | Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors. | Cancer Chemother Pharmacol | 2009 Jun | Kolesar J | doi: 10.1007/s00280-008-0845-0 |
28624910 | Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy? | J Cancer Res Clin Oncol | 2017 Aug | Mannargudi MB | doi: 10.1007/s00432-017-2457-8 |
24756820 | Targeting ribonucleotide reductase M2 subunit by small interfering RNA exerts anti-oncogenic effects in gastric adenocarcinoma. | Oncol Rep | 2014 Jun | Kang W | doi: 10.3892/or.2014.3148 |
20825972 | Expression of ribonucleotide reductase M2 subunit in gastric cancer and effects of RRM2 inhibition in vitro. | Hum Pathol | 2010 Dec | Morikawa T | doi: 10.1016/j.humpath.2010.06.001 |
18278438 | A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas. | Invest New Drugs | 2008 Aug | Attia S | doi: 10.1007/s10637-008-9123-6 |
24637958 | The expression of ribonucleotide reductase M2 in the carcinogenesis of uterine cervix and its relationship with clinicopathological characteristics and prognosis of cancer patients. | PLoS One | 2014 Mar 17 | Su YF | doi: 10.1371/journal.pone.0091644 |
20927319 | Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. | Neoplasia | 2010 Oct | Fujita H | - |
14729598 | In vitro characterization of enzymatic properties and inhibition of the p53R2 subunit of human ribonucleotide reductase. | Cancer Res | 2004 Jan 1 | Shao J | - |
26001082 | Ribonucleotide reductase subunit M2 predicts survival in subgroups of patients with non-small cell lung carcinoma: effects of gender and smoking status. | PLoS One | 2015 May 22 | Mah V | doi: 10.1371/journal.pone.0127600 |
25213022 | Prognostic and therapeutic significance of ribonucleotide reductase small subunit M2 in estrogen-negative breast cancers. | BMC Cancer | 2014 Sep 11 | Zhang H | doi: 10.1186/1471-2407-14-664. |
26718430 | Investigation of some DNA repair genes association in non small cell lung cancer. | Cell Mol Biol (Noisy-le-grand) | 2015 Dec 19 | Coskunpinar E | - |
23335963 | Differential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoprotein. | PLoS One | 2013 | Bhutia YD | doi: 10.1371/journal.pone.0053436 |
21965764 | Expression status of ribonucleotide reductase small subunits hRRM2/p53R2 as prognostic biomarkers in stage I and II non-small cell lung cancer. | Anticancer Res | 2011 Oct | Hsu NY | - |
26093293 | E2F1 promote the aggressiveness of human colorectal cancer by activating the ribonucleotide reductase small subunit M2. | Biochem Biophys Res Commun | 2015 Aug 21 | Fang Z | doi: 10.1016/j.bbrc.2015.06.103 |
24155212 | Expression of RRM1 and RRM2 as a novel prognostic marker in advanced non-small cell lung cancer receiving chemotherapy. | Tumour Biol | 2014 Mar | Wang L | doi: 10.1007/s13277-013-1255-4 |
24360663 | The prognostic value of ribonucleotide reductase small subunit M2 in predicting recurrence for prostate cancers. | Urol Oncol | 2014 Jan | Huang Y | doi: 10.1016/j.urolonc.2013.08.002. |
21166702 | Ribonucleotide reductase M2 subunit is a novel diagnostic marker and a potential therapeutic target in bladder cancer. | Histopathology | 2010 Dec | Morikawa T | doi: 10.1111/j.1365-2559.2010.03725.x. |
28327155 | Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2. | Mol Cancer | 2017 Mar 21 | Tu M | doi: 10.1186/s12943-017-0619-6. |
27517489 | Suppression of c-Myc and RRM2 expression in pancreatic cancer cells by the sphingosine kinase-2 inhibitor ABC294640. | Oncotarget | 2016 Sep 13 | Lewis CS | doi: 10.18632/oncotarget.11112. |
28507282 | P53 suppresses ribonucleotide reductase via inhibiting mTORC1. | Oncotarget | 2017 Jun 20 | He Z | doi: 10.18632/oncotarget.17440. |
28797284 | Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2). | J Exp Clin Cancer Res | 2017 Aug 10 | Xia G | doi: 10.1186/s13046-017-0579-0. |
28782484 | Gene Expression Meta-Analysis of Potential Metastatic Breast Cancer Markers. | Curr Mol Med | 2017 | Bell R | doi: 10.2174/1566524017666170807144946. |